A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes
- Registration Number
- NCT01589159
- Lead Sponsor
- Tao OUYANG
- Brief Summary
This is a single-center, open-lable, non-comparative, prospective, phase Ⅱ efficacy and safety study. Eligible patients are enrolled in a single group. The investigators propose to determine the efficacy and safety of low-dose metronomic chemotherapy with Etoposide/Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines and/or Taxanes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 54
Inclusion Criteria
- female patients between 18 and 65 years old
- patients with metastatic breast cancer previousely treated with A/T
- able and willing to give consent to participate in the study
Read More
Exclusion Criteria
- pregnant or lactating females
- other tumor history
- instable complication (e.g., myocardial infarction within 6 months,arrhythmia, unstable diabetes, hypercalcemia) or uncontrolled infection
- concurrent disease or condition that would make the patient inappropriate for study participation
- resist to participate in the study
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Experimental Capecitabine - Experimental Etoposide -
- Primary Outcome Measures
Name Time Method Clinical benefit rate 24 weeks after the treatment Clinical benefit is defined as CR, PR, SD≥24 weeks.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Peking University Cancer Hospital & Institute
🇨🇳Beijing, Beijing, China